Abiopharma

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update

Supernus Announces Third Quarter 2025 Financial Results

Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences

Bruker Announces Quarterly Common Stock Dividend and Preferred Stock Dividend

AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

Alvotech kynnir afkomu fyrstu níu mánaða ársins og ræðir nýjustu áfanga í rekstri félagsins þann 13. nóvember nk.

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody